tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Scorpion Stings D065008 1 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Retrognathia D063173 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Netherton Syndrome D056770 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Multiple Pulmonary Nodules D055613 2 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Finn L et al. Epstein-Barr virus infections in children after transplantation of the small intestine. 1998 Am. J. Surg. Pathol. pmid:9500771
Randhawa PS et al. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. 1993 Am. J. Surg. Pathol. pmid:7680544
Minervini MI et al. Acute renal allograft rejection with severe tubulitis (Banff 1997 grade IB). 2000 Am. J. Surg. Pathol. pmid:10757402
Randhawa PS et al. Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. 1996 Am. J. Surg. Pathol. pmid:8772784
Spada M et al. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. 2006 Am. J. Transplant. pmid:16771811
Saliba F et al. Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial. 2017 Am. J. Transplant. pmid:28133906
de Fijter JW et al. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. 2017 Am. J. Transplant. pmid:28027625
Trofe-Clark J et al. Immunosuppression, generic drugs and the FDA. 2012 Am. J. Transplant. pmid:22176626
Latran M Response to Klintmalm on the use of generic immunosuppression. 2012 Am. J. Transplant. pmid:22176636
Krenzien F et al. Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus. 2017 Am. J. Transplant. pmid:27754593
Saikali JA et al. Sirolimus may promote thrombotic microangiopathy. 2003 Am. J. Transplant. pmid:12603218
Borrows R et al. Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. 2004 Am. J. Transplant. pmid:15476485
Frassetto LA and Benet LZ Pharmacogenomics and transplantation: where are we? 2004 Am. J. Transplant. pmid:15147415
Hirsch HH et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. 2013 Am. J. Transplant. pmid:23137180
Mujtaba MA et al. Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients. 2014 Am. J. Transplant. pmid:25179306
Koefoed-Nielsen PB et al. Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. 2002 Am. J. Transplant. pmid:12099520
Shihab FS et al. Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study. 2013 Am. J. Transplant. pmid:23167508
Alloway RR et al. A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. 2012 Am. J. Transplant. pmid:22759200
Hesselink DA et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. 2005 Am. J. Transplant. pmid:15816878
Byrne GW et al. Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. 2005 Am. J. Transplant. pmid:15816881
Lucey MR et al. A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status. 2005 Am. J. Transplant. pmid:15816894
Pillebout E et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). 2005 Am. J. Transplant. pmid:15816895
Madariaga ML et al. Kidney-induced cardiac allograft tolerance in miniature swine is dependent on MHC-matching of donor cardiac and renal parenchyma. 2015 Am. J. Transplant. pmid:25824550
Vanrenterghem Y et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. 2005 Am. J. Transplant. pmid:15636615
Sindhi R et al. Enhanced donor-specific alloreactivity occurs independently of immunosuppression in children with early liver rejection. 2005 Am. J. Transplant. pmid:15636616
Shergill AK et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. 2005 Am. J. Transplant. pmid:15636619
Tydén G et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. 2005 Am. J. Transplant. pmid:15636623
Woodle ES et al. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. 2005 Am. J. Transplant. pmid:15636625
Mian AN et al. Mycoplasma hominis septic arthritis in a pediatric renal transplant recipient: case report and review of the literature. 2005 Am. J. Transplant. pmid:15636628
Padiyar A et al. Clinical predictors of proteinuria after conversion to sirolimus in kidney transplant recipients. 2010 Am. J. Transplant. pmid:20055793
Hardinger KL et al. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. 2010 Am. J. Transplant. pmid:20055811
Bhorade SM et al. Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation. 2003 Am. J. Transplant. pmid:14629288
Pondrom S The AJT report. 2008 Am. J. Transplant. pmid:18324976
Fan DM et al. Successful ABO-incompatible living-related intestinal transplantation: a 2-year follow-up. 2015 Am. J. Transplant. pmid:25808777
Okabayashi T et al. Mobilization of host stem cells enables long-term liver transplant acceptance in a strongly rejecting rat strain combination. 2011 Am. J. Transplant. pmid:21883903
Hellemons ME et al. Former smoking is a risk factor for chronic kidney disease after lung transplantation. 2011 Am. J. Transplant. pmid:21883906
Maes BD et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. 2002 Am. J. Transplant. pmid:12484345
Min SI et al. Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. 2013 Am. J. Transplant. pmid:23734831
Bunnapradist S et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. 2013 Am. J. Transplant. pmid:23279614
Ceschi A et al. Acute calcineurin inhibitor overdose: analysis of cases reported to a national poison center between 1995 and 2011. 2013 Am. J. Transplant. pmid:23279718
Teuteberg JJ et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. 2010 Am. J. Transplant. pmid:19889126
Haufroid V et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. 2006 Am. J. Transplant. pmid:17049058
Shapiro R et al. Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation. 2007 Am. J. Transplant. pmid:17908272
Rush D et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. 2007 Am. J. Transplant. pmid:17908280
Turgut F and Akcay A Renal function estimation in cirrhosis. 2009 Am. J. Transplant. pmid:19519814
Irish WD et al. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. 2011 Am. J. Transplant. pmid:21564522
Tricot L et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. 2009 Am. J. Transplant. pmid:19519819
Friman S et al. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. 2011 Am. J. Transplant. pmid:21564523
Kofler S et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. 2009 Am. J. Transplant. pmid:19519820
Margreiter R et al. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. 2008 Am. J. Transplant. pmid:18510632